- Home
- FONR vs MCRB Comparison
FONR vs MCRB Comparison
Compare FONR & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FONR | MCRB |
|---|---|---|
| Founded | 1978 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.8M | 139.7M |
| IPO Year | 1995 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FONR | MCRB |
|---|---|---|
| Price | $18.54 | $8.75 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.33 |
| AVG Volume (30 Days) | 66.4K | ★ 96.7K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | 1.16 | ★ 2.40 |
| Revenue | $104,351,318.00 | ★ $126,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.02 | ★ $3.70 |
| Revenue Growth | 1.43 | ★ 1672.24 |
| 52 Week Low | $12.00 | $0.36 |
| 52 Week High | $18.86 | $29.98 |
Technical Indicators
Market Signals| Indicator | FONR | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 29.29 |
| Support Level | $18.49 | $7.12 |
| Resistance Level | $18.73 | $16.14 |
| Average True Range (ATR) | 0.08 | 1.06 |
| MACD | -0.08 | -0.30 |
| Stochastic Oscillator | 20.92 | 11.18 |
Price Performance
Historical ComparisonAbout FONR Fonar Corporation
Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.